ArticleOxford medical case reports2025
Case report: the challenges of psychogenic polydipsia.
Article in Oxford medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: We describe a case report of a 71-year-old with a long history of Paranoid Schizophrenia presenting with psychogenic polydipsia. Background: Psychogenic polydipsia is a rare and challenging complication of Paranoid Schizophrenia. Research is limited with regards to how to treat this effectively, however the management normally involves fluid restriction and behavioural therapy. Method: We looked through his history and liaised with multiple specialities to compile this report. Result: This patient has long history of psychogenic polydipsia. More recently he presented with his chronic hyponatremia. To aid reduction of his hyponatraemia, his duloxetine was stopped, and his olanzapine dose reduced. Conclusions: There is evidence in the role of naltrexone in reducing compulsive drinking. We trialled this at 25 mg and the patient's drinking behaviour has reduced in the community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.